AR 601
Alternative Names: AR-601Latest Information Update: 27 Mar 2023
At a glance
- Originator Aimmune Therapeutics
- Class Antiallergics; Food allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Food hypersensitivity
Most Recent Events
- 14 Feb 2023 Phase-I clinical trials in Food hypersensitivity in USA (unspecified route) (Aimmune Therapeutics pipeline, February 2023)